Study population
epilepsy, psychiatric, NF1, mental retardation, allergic reactions
DISEASES, ALLERGIC REACTION, EPILEPSY
Inclusion criteria are defined as follows: (1) Group 1: NS, Group 2: NF1 (both genetically assured); (2) age ≥ 16 years; (3) signed informed consent of the adolescent (16–17 years of age) who is capable to give his consent and understand the aim and rationale of the study and of the legal guardian; (4) signed informed consent of persons who are ≥ 18 years old and capable to give their consent. In case of doubts, an independent medical practitioner will evaluate the capacity to consent; (5) male and female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country.Exclusion criteria are (1) epilepsy, (2) participants taking medication with known central nervous system (CNS) effects, (3) severe mental retardation, (4) side effects during previous medication with and contraindications for LTG and/or LOV and/or transcranial magnetic stimulation (TMS), (5) psychiatric diseases, (6) previous history of allergic reactions with LTG and LOV medications, (7) potentially unreliable patients, (8) patients who are not suitable for the study in the opinion of the investigator, (9) pregnancy (incl. positive urine pregnancy test) and (10) persons who are incapable of giving consent or do not understand the aim or rationale of the study.